Interaction Guide · Research summary

Can I take Panax Ginseng with Acalabrutinib?

Review Panax Ginseng with Acalabrutinib: possible adverse effects, preparation details, evidence limits, and sources.

Prepared by Dr. Edward M.Kim, PharmD · Clinical Director, SupplementSafety editorial team

Research summary published · Prepared · Editorial update

The short answer

A specific increase in bleeding from Panax ginseng with acalabrutinib has not been established. Have concentrated supplements reviewed because the cancer medicine itself can cause bleeding or low platelets.

What this answer covers

Oral acalabrutinib with Panax ginseng products. Defined herbal preparations in aspirin studies are distinct from this cancer-drug pair.

Supplement or preparation
Panax ginseng
Medication ingredient
acalabrutinib

Check the prescribed treatment

This review concerns oral acalabrutinib used for selected blood cancers. CALQUENCE tablets use the maleate salt, while capsules contain the free-base form. The formulations have different acid-reducer instructions, so follow the product actually prescribed and keep the full treatment regimen intact.

The human trial was largely negative

A randomized study tested defined Panax ginseng and turmeric preparations alone and with aspirin in healthy volunteers. Overall clotting and platelet measures were not meaningfully worsened, and no significant bleeding was reported. Some individual platelet-assay responses occurred, so the findings should not be described as proving no biological effect.

The preparation and population limit the conclusion

The study’s Panax ginseng preparation cannot be replaced by American ginseng, another species, or assumed to represent every steamed, extracted or mixed product. No exact combination trial was identified.

Use individualized precautions

Show the supplement and other medicines to the oncology team. Follow blood-count monitoring and report new bleeding or bruising promptly. Do not use the negative trial to override a low platelet count, and do not invent a dose gap or stop the cancer medicine yourself.

Evidence and practical considerations

Side effects & toxicity

The original bleeding claim is insufficient; a human trial with another drug was largely negative and does not establish target-pair safety.

Exact scope
Oral acalabrutinib with Panax ginseng products. Defined herbal preparations in aspirin studies are distinct from this cancer-drug pair. with RxNorm 1986808 IN acalabrutinib. Exact current oral product: CALQUENCE oral acalabrutinib maleate tablets. Salt, formulation and regimen distinctions explicit.
Medication form and route
Oral

What remains uncertain

  • No exact combination outcome study; different-drug healthy-volunteer null retained. Exact botanical species and preparation matter.

Factors that may matter: Exact oral formulation and supplement preparation; Drug exposure versus clinical outcomes; Dose and duration; Platelet count and neurological symptoms.

Research conclusion: insufficient evidence · Evidence assessment: low

Read the supporting source summaries

Source 1: Current original prescribing information

dailymed.nlm.nih.gov · Source check Sep 11, 2026

Population: Patients prescribed the exact oral formulation.

Bleeding/low platelet warnings; CYP3A induction may lower exposure; maleate-tablet PPI null differs from capsule restriction.

How this applies: RxNorm 1986808 IN acalabrutinib. Exact current oral product: CALQUENCE oral acalabrutinib maleate tablets. Salt, formulation and regimen distinctions explicit.

Exact product source, not a direct study of every supplement. Population, active metabolites and formulation scope retained.

Source 2: Original clinical research

pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026

Population: 25 healthy volunteers allocated for each herbal preparation.

No clinically relevant overall platelet/coagulation effect or significant bleeding; occasional individual arachidonic-acid assay responses.

How this applies: Exact preparation/population/endpoints only; applicability to acalabrutinib independently assessed.

Abstract-only exact formulations not fully characterized here. Different drug/population; turmeric is not isolated curcumin and P. ginseng is not American ginseng.

Source 3: Medication terminology

rxnav.nlm.nih.gov · Source check Sep 11, 2026

Population: Terminology.

acalabrutinib is IN.

How this applies: Exact ingredient.

Not clinical evidence.

Research assessment: · Open full citations ↗

Review and change history

Publication status
Published research summary
Clinical review
Not yet recorded
DateUpdate
Research summary published
Article prepared
Sources checked and article drafted.

Article revision: 71e37590e9ad52ae

This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.

Full citations require verification. Reading this answer and the source summaries does not.

Taking other supplements or medications?

Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.

Open the interaction checker

Information, not medical advice. Do not change prescribed treatment based on this guide.